(Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met…
DATROWAY® Demonstrates Significant Survival Benefit Over Chemotherapy in First-Line Metastatic Triple-Negative Breast Cancer in TROPION-Breast02 Trial Positive results from the pivotal TROPION-Breast02 phase 3 trial have shown that DATROWAY® (datopotamab deruxtecan) delivers a statistically significant and clinically meaningful improvement in…
DESTINY-Breast05 Phase III Trial Demonstrates ENHERTU® Significantly Reduces Recurrence Risk in High-Risk HER2-Positive Early Breast Cancer Positive results from the DESTINY-Breast05 Phase III trial have demonstrated that ENHERTU® (fam-trastuzumab deruxtecan-nxki) provides a highly statistically significant and clinically meaningful improvement in…
Genmab Reports Promising New Data Showing Rina-S® Demonstrates Strong Anti-Tumor Activity in Advanced Endometrial Cancer Genmab A/S (Nasdaq: GMAB) announced new and encouraging results from its Phase 1/2 RAINFOL™-01 clinical trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha…
Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on integrating advanced engineering with cutting-edge laboratory and in silico research to accelerate drug discovery, today announced that new data from its ongoing Phase 2 study of EIK1001 (TeLuRide-005) will be…
Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the treatment of pain associated with osteoarthritis (OA) in dogs. Lenivia represents a novel monoclonal antibody therapy, developed over a decade of rigorous scientific research, designed to…
Augurex Life Sciences Corp., a leading innovator in autoimmune-based diagnostics, today announced a strategic partnership with MitogenDx, a Canadian specialty laboratory focused on autoimmune and rheumatology testing. Under the agreement, MitogenDx will offer Augurex’s JOINTstat® blood test, significantly expanding access…
Lasso, a next-generation food technology company, today officially launched with the unveiling of its proprietary Lasso SpinTech, a physics-based system designed to revolutionize how modern packaged foods are made. The breakthrough technology blends protein and fiber in a completely new…
Oticara, a clinical-stage pharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS), announced encouraging results from its Phase 2 OT-007B clinical trial. The study evaluated Oticara’s proprietary nasal-mucosa-optimized steroid cream in patients suffering from persistent CRS symptoms after…
Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis…